Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Breast Cancer : Targets and Therapy logoLink to Breast Cancer : Targets and Therapy
. 2012 Mar 8;4:33. doi: 10.2147/BCTT.S31163

Retraction

PMCID: PMC3846860  PMID: 24367192

The Editor-in-Chief and Publisher of Breast Cancer: Targets and Therapy have been alerted to unacceptable levels of duplication with previously published papers. All four papers were submitted by Dr Rajeev Singhai.

It is worth noting that all papers were peer-reviewed by a minimum of two peer-reviewers and the Editor-in-Chief of Breast Cancer: Targets and Therapy before publication. The papers concerned are:

Patil VW, Tayade MB, Pingale SA, et al. The p53 breast cancer tissue biomarker in Indian women. Breast Cancer: Targets and Therapy. 2011;3:71–78.

Singhai R, Patil AV, Patil VW. Cancer biomarker HER-2/neu in breast cancer in Indian women. Breast Cancer: Targets and Therapy. 2011;3:21–26.

Patil AV, Bhamre RS, Singhai R, Tayade MB, Patil VW. Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women. Breast Cancer: Targets and Therapy. 2011;3:27–33.

Patil VW, Singhai R, Patil AV, Gurav PD. Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women. Breast Cancer: Targets and Therapy. 2011;3:9–19.


Articles from Breast Cancer : Targets and Therapy are provided here courtesy of Dove Press

RESOURCES